GE HealthCare has secured CE Mark certification for its MINItrace Magni cyclotron and broadened its PETtrace Solid Target Platform to manufacture Copper-64.
Both developments target the production infrastructure needed by healthcare institutions to run positron emission tomography (PET) programmes and pursue radiopharmaceutical research.
The newly certified MINItrace Magni is an automated, self-shielded cyclotron developed for in-house radioisotope manufacturing.
Intended to produce Carbon-11, Fluorine-18, Nitrogen-13, and Oxygen-15, the compact unit automates beam tuning, target irradiation, and target preparation via a three-click operational interface.
When operated alongside the company's TRACERcenter Solutions, the system fits into wider PET radiopharmacy setups to accommodate specific departmental and tracer manufacturing demands.
At the same time, GE HealthCare has added Copper-64 capabilities to its PETtrace Solid Target Platform. The solid-target hardware was initially introduced for Gallium-68 in 2022 and subsequently adapted for Zirconium-89 in early 2026.
The latest addition broadens the isotope range that can be processed using PETtrace equipment, allowing facilities to expand their tracer output.
Copper-64 provides diagnostic imaging and is being investigated alongside Copper-67 agents as a potential diagnostic and therapeutic theranostic pairing.
Clinical researchers are currently studying compounds labelled with Copper-64 in prostate cancer as well as human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
To support this work, the company couples cyclotrons and targetry with synthesis chemistry and imaging tools.
GE HealthCare molecular imaging vice-president Erez Levy said: “The molecular imaging landscape is being reshaped by the expansion of theranostics, the introduction of new PET tracers, and demand across oncology, neurology and cardiology.
“As tracer portfolios broaden, healthcare providers need reliable access to radioisotopes and the flexibility to respond to changing clinical needs.
“That calls for a longer-term view of radiopharmaceutical production—one that supports established services while allowing institutions to prepare for new clinical and research applications.”
Earlier this month, GE HealthCare agreed to acquire SOFIE Biosciences, a contract manufacturing organisation (CMO) specialising in PET radiopharmaceuticals, from Trilantic North America in a $945m deal.
